Teva Leapfrogs Viatris With First US Sandostatin LAR Generic Launch
Long-Acting Treatment For Acromegaly Had No Patent Protection, But Difficult To Make
Executive Summary
Teva has begun shipping the first US generic version of Novartis’ Sandostatin LAR Depot – a synthetic polypeptide that is part of a difficult-to-manufacture class of long-acting polymers.